Ann: POSITIVE HBV IN VIVO DATA, page-77

First 77 Last

Share
Profile

Follow
Hoyland

4,015 Posts.

127

11/03/16

18:50

Post #: 17255353
Share

Originally posted by rgc68 ↑

I would say none of these are investment grade companies. They are research companies whose research is being funded by shareholders (instead of, or as well as, universities). Back in the day I started out in molecular biology and the big problem then has still not been adequately solved - targeted delivery of nucleic acids. The body has a thing about nucleic acids - they can represent a threat, and they are generally dealt with swiftly (aside from some peculiar exceptions which I've not heard well-explained). Therefore injecting them into the bloodstream as naked NA is generally not going to work, and clearly ingesting them (as a tablet) won't work at all. The trouble with viral vectors is that they are rarely highly specific in terms of targeting tissues, don't generate very high concentrations, and they don't persist in the body. Using autologous stem cells might be a better means of delivering NA but the constructs would need a way of persisting in daughter cells. There's a HUGE amount more knowledge now compared to when I worked in the area, but delivery is still the issue. And with a hyper virulent virus such as HBV, close to the perfect pathogen, getting enough in to inactivate it is an enormous task. Antiviral enzyme inhibitors remain the front runners in both HBV and HIV.

Expand

It sounds like you do not believe that gene therapy or RNAi will work under any circumstances. There are billions of dollars being invested in these technologies and so someone must think they are in with a chance - in addition to the hundreds of scientists working in these fields.

Maybe, HBV is not the next best option for Benitec to tackle but, from what you are saying, nothing else would be much better.

BLT Price at posting: 12.5¢ Sentiment: None Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

CBA breaks trading record on strong day for Aussie financials

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

As Nvidia cools, we're looking to Aussie AI

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

There are more pages in this discussion • 20 more messages in this thread...

First 77 Last

Add BLT (ASX) to my watchlist

Ann: POSITIVE HBV IN VIVO DATA, page-77

Top Stories

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

CBA breaks trading record on strong day for Aussie financials

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

As Nvidia cools, we're looking to Aussie AI

Shekel Brainweigh investor presentation webinar – the future of retail automation

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Featured News